Here are the DEF 14A proxy statements from Biohaven Ltd. (BHVN) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow BHVN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BHVN filings page.
Biohaven Ltd. is asking shareholders to approve three items at its 2026 annual meeting: elect three directors to serve until 2029, ratify Ernst & Young LLP as auditor for 2026, and approve on an advisory basis executive compensation.
The proxy highlights 2025 R&D progress, including extracellular protein degrader programs in IgA nephropathy and Graves’ disease, an epilepsy candidate opakalim with seizure reduction data, and obesity drug taldefgrobep entering Phase 2. Oncology antibody–drug conjugate programs and several discovery-stage assets are also described.
The board has eight members, six deemed independent, with a combined chair/CEO and a lead independent director. As of March 3, 2026, 150,420,584 common shares were outstanding; two institutional holders each own more than 5%. The company emphasizes financial discipline, equity ownership guidelines, and standard NYSE-aligned governance practices.